Genomic Insights into Probiotic Lactococcus lactis T-21, a Wild Plant-Associated Lactic Acid Bacterium, and Its Preliminary Clinical Safety for Human Application
Microorganisms · 10.02.2025 · 13 (2) · 388
DOI: 10.3390/microorganisms13020388 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microorganisms, online erschienen am 10.02.2025. Verfasst von Masanori Fukao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nissin York Co., Ltd., 3-6-11 Higashi-Nihonbashi Chuo-ku, Tokyo 103-0004, Japan. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lactococcus lactis T-21 is a lactic acid bacterium isolated from wild cranberries in Japan that demonstrates significant immunomodulatory properties and has been incorporated into commercial health products. However, probiogenomic analyses specific to T-21 have remained largely unexplored. This study performed a thorough genomic characterisation of T-21 and evaluated its safety in initial clinical trials. Genomic analysis revealed substantial genetic diversity and metabolic capabilities, including enhanced fermentative potential demonstrated by its ability to metabolise a wide range of plant-derived carbohydrates, and genetic determinants associated with exopolysaccharide biosynthesis and nisin production, distinguishing T-21 from domesticated dairy strains. These attributes, reflective of its wild plant origin, may contribute to its metabolic versatility and unique probiotic functionalities. A preliminary clinical trial assessing the safety of T-21-fermented milk in healthy Japanese adults indicated no significant adverse outcomes, corroborating its safety for human consumption. Together, these findings support the feasibility of utilising non-dairy, wild plant-origin strains in dairy fermentation processes as probiotics. This study expands our understanding of the genomic basis for T-21’s probiotic potential and lays the groundwork for further investigations into its functional mechanisms and potential applications in promoting human health.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nissin York Co., Ltd., 3-6-11 Higashi-Nihonbashi Chuo-ku, Tokyo 103-0004, Japan.
- Global Innovation Center, Nissin Foods Holdings Co., Ltd., 2100 Tobukimachi, Hachioji-shi 192-0001, Tokyo, Japan.
- Laboratory of Microbial Technology, Division of Systems Bioengineering, Department of Bioscience and Biotechnology, Faculty of Agriculture, Graduate School, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Ja…
ORCID-Profile: Masanori Fukao, Takuya Sugimoto, Takeshi Zendo
Zitieren
APA
Fukao, M., Tagawa, K., Sunada, Y., Uehara, K., Sugimoto, T., Zendo, T., Nakayama, J., & Segawa, S. (2025). Genomic Insights into Probiotic Lactococcus lactis T-21, a Wild Plant-Associated Lactic Acid Bacterium, and Its Preliminary Clinical Safety for Human Application. Microorganisms, 13(2), 388. https://doi.org/10.3390/microorganisms13020388
Vancouver
Fukao M, Tagawa K, Sunada Y, Uehara K, Sugimoto T, Zendo T, et al. Genomic Insights into Probiotic Lactococcus lactis T-21, a Wild Plant-Associated Lactic Acid Bacterium, and Its Preliminary Clinical Safety for Human Application. Microorganisms. 2025;13(2):388. doi:10.3390/microorganisms13020388
BibTeX
@article{Fukao2025,
author = {Fukao, Masanori and Tagawa, Keisuke and Sunada, Yosuke and Uehara, Kazuya and Sugimoto, Takuya and Zendo, Takeshi and Nakayama, Jiro and Segawa, Shuichi},
title = {Genomic Insights into Probiotic Lactococcus lactis T-21, a Wild Plant-Associated Lactic Acid Bacterium, and Its Preliminary Clinical Safety for Human Application},
journal = {Microorganisms},
year = {2025},
volume = {13},
number = {2},
pages = {388},
doi = {10.3390/microorganisms13020388}
}
EUVIMED